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***Dear Editor,***

Prevalence and mortality of liver fibrosis continue to grow (Pimpin et al., 2018\[[@R17]\]; Weiskirchen and Tacke, 2016\[[@R24]\]; Leist et al., 2017\[[@R13]\]; Godoy et al., 2013\[[@R6]\]). Liver fibrosis occurs as a consequence of chronic liver damage due to various causes, such as viral infections, super-nutrition, metabolic disorders or genetic diseases (Godoy et al., 2013\[[@R6]\]; Ghallab et al., 2019\[[@R5]\]).

Recently, Winkler and colleagues performed a comprehensive study to analyze the role of miRNA in liver fibrosis and the development of hepatocellular cancer (Winkler et al., 2020\[[@R25]\]). For this purpose, the authors generated mice that express a constitutively active variant of serum response factor (SRF) in the liver (Winkler et al., 2020\[[@R25]\]). SRF regulates numerous biological processes (Olson and Nordheim 2010\[[@R16]\]; Ohrnberger et al., 2015\[[@R15]\]) and the mice develop hyperproliferative nodules that progress to HCC (Ohrnberger et al., 2015\[[@R15]\]). In this murine HCC model, the authors identified eight miRNA hubs and 54 target genes that regulate components of the fibrotic extracellular matrix (Winkler et al., 2020\[[@R25]\]). Hubs are defined as nodes in a transcriptional regulatory network with an unusual high number of connections (Anastasiadou et al., 2018\[[@R2]\]). Here, the miRNA families let-7, miR-30 as well as miR-29c, miR-335 and miR-338 represent central antifibrotic miRNAs (Winkler et al., 2020\[[@R25]\]). Importantly, these antifibrotic miRNAs (with the exception of miR-335) are regulated by the transcription factor PPARG (Winkler et al., 2020\[[@R25]\]). Therefore, the authors conclude that stimulating this transcription factor may represent a strategy for antifibrotic therapy.

Currently, numerous research activities are performed to identify or optimize therapies for chronic liver disease (Trauner et al., 2017\[[@R22]\]; Svinka et al., 2017\[[@R20]\]; Ghallab et al., 2016\[[@R3]\]; Schliess et al., 2014\[[@R18]\]). A particular challenge are the different etiologies with toxic (Grinberg et al., 2014\[[@R8]\]; 2018\[[@R7]\]; Albrecht et al., 2019\[[@R1]\]; Sezgin et al., 2018\[[@R19]\]), viral (Kazankov et al., 2014\[[@R12]\]; Theise et al., 2018\[[@R21]\]; Maponga et al., 2018\[[@R14]\]), cholestatic (Vartak et al., 2016\[[@R23]\]; Ghallab et al., 2019\[[@R4]\]; Hessel-Pras et al., 2020\[[@R9]\]) and genetic (Hudert et al., 2019\[[@R10]\]; Jansen et al., 2017\[[@R11]\]) mechanisms. A strength of the present study of Winkler et al.\[[@R25]\] is that the authors have identified hubs to target numerous antifibrotic genes simultaneously, independent of the etiology. Future studies will show, whether hub-targeting therapies will indeed ameliorate fibrosis and delay progression to HCC in mouse tumor models.
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